A REVIEW OF EVEROLIMUS-EXEMESTANE COMBINATION TREATMENT IN METASTATIC BREAST CANCER - A REAL-WORLD CLINICAL EXPERIENCE

被引：0
|
作者：
Agarwal, Anupriya [1 ,2 ]
Beith, Jane M. [1 ,2 ]
McNeil, Catriona [1 ,2 ]
机构：
[1] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[2] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
265
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [1] A REVIEW OF EVEROLIMUS-EXEMESTANE COMBINATION TREATMENT IN METASTATIC BREAST CANCER: A REAL-WORLD CLINICAL EXPERIENCE
    Agarwal, A.
    McNeil, C.
    Beith, J. M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 51 - 51
  • [2] Efficacy and tolerability of Everolimus-Exemestane combination therapy in metastatic breast cancer patients: experience in Real Life
    Cocciolone, V.
    Cannita, K.
    Tessitore, A.
    Rinaldi, L.
    Irelli, A.
    Dal Mas, A.
    Calvisi, G.
    Bafile, A.
    Alesse, E.
    Ricevuto, E.
    Ficorella, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 24 - 24
  • [3] From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data
    Abdel-Razeq, Hikmat
    Sharaf, Baha'
    Abdulelah, Hazem
    Abdel-Razeq, Nayef
    Salam, Mourad
    Inserat, Bayan
    Bater, Rayan
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 184 - 189
  • [4] Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
    Li, Yi
    Xie, Yizhao
    Gong, Chengcheng
    Zhao, Yannan
    Zhang, Jian
    Zhang, Sheng
    Wang, Leiping
    Chen, She
    Hu, Xichun
    Wang, Biyun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 607 - 615
  • [5] Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer
    Fukudo, Masahide
    Ishibashi, Kei
    Kitada, Masahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1707 - 1715
  • [6] Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer
    Masahide Fukudo
    Kei Ishibashi
    Masahiro Kitada
    Investigational New Drugs, 2021, 39 : 1707 - 1715
  • [7] Fulvestrant versus everolimus plus exemestane for patients with metastatic breast cancer resistant to aromatase inhibitors: Clinical experience from real world.
    Li, Yi
    Xie, Yizhao
    Zhao, Yannan
    Hu, Xi-Chun
    Zhang, Jian
    Chen, Shen
    Gong, Chengcheng
    Zhang, Sheng
    Wang, Leiping
    Wang, Biyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.
    Wang, Ying
    Le, Dan
    Camateros, Pierre
    Lohrisch, Caroline A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] THE REAL-WORLD COST AND EFFECTIVENESS OF EVEROLIMUS IN METASTATIC BREAST CANCER IN THE CZECH REPUBLIC
    Rihova, B.
    Demlova, R.
    Cerna, R.
    VALUE IN HEALTH, 2018, 21 : S19 - S19
  • [10] Everolimus in heavily pretreated metastatic breast cancer: Is real world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Gupta, S.
    Ghosh, J.
    Gulia, S.
    INDIAN JOURNAL OF CANCER, 2016, 53 (03) : 464 - 467
12345